Evidence map›Paper›PMID 33065179›Full record

ReviewDiabetes research and clinical practice2020

Continuous glucose monitoring: The achievement of 100 years of innovation in diabetes technology.

Rodolfo J Galindo, Grazia Aleppo

Abstract readReview
In one paragraph

Review in Diabetes research and clinical practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Continuous glucose monitoring in type 2 diabetes: a systematic review of barriers and opportunities for care improvement.International journal for quality in health care : journal of the International Society for Quality in Health Care · 2025
    Pooled it
  3. Guideline
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Observational
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rodolfo J GalindoDivision of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, 69 Jesse Hill Jr. Dr., Glenn Building, Suite 202, Atlanta, GA, 30303, USA. Electronic address: rodolfo.galindo@emory.edu.
Grazia AleppoDivision of Endocrinology, Metabolism and Molecular Medicine, Feinberg School of Medicine, Northwestern University, 645 N. Michigan Ave, Suite 530, Chicago, IL 60611, USA. Electronic address: aleppo@northwestern.edu.

Funding

Translational Research Core - Engagement and Behavior ChangeP30DK111024 · NIDDK · EMORY UNIVERSITY · PI Mohammed Kumail Ali · 2016 to 2026
$13.4M
Use of Continuous Glucose Monitoring (CGM) in End-Stage Renal Disease(ESRD) Patients with Type 2 DiabetesK23DK123384 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI GALINDO, RODOLFO · 2020 to 2024
$934k
NIDDK NIH HHS K23 DK123384NIDDK NIH HHS P30 DK111024
6 · The paper itself

Abstract

Monitoring of glucose levels is essential to effective diabetes management. Over the past 100 years, there have been numerous innovations in glucose monitoring methods. The most recent advances have centered on continuous glucose monitoring (CGM) technologies. Numerous studies have demonstrated that use of continuous glucose monitoring confers significant glycemic benefits on individuals with type 1 diabetes (T1DM) and type 2 diabetes (T2DM). Ongoing improvements in accuracy and convenience of CGM devices have prompted increasing adoption of this technology. The development of standardized metrics for assessing CGM data has greatly improved and streamlined analysis and interpretation, enabling clinicians and patients to make more informed therapy modifications. However, many clinicians many be unfamiliar with current CGM and how use of these devices may help individuals with T1DM and T2DM achieve their glycemic targets. The purpose of this review is to present an overview of current CGM systems and provide guidance to clinicians for initiating and utilizing CGM in their practice settings.

Indexed as

Blood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2HumansLongitudinal StudiesTechnologyBlood GlucoseAGPAmbulatory Glucose ProfileCGMContinuous glucose monitoringHbA1cIntermittently scanned CGMisCGMReal-time CGMrtCGMType 1 diabetesType 2 diabetes

Identifiers

PMID33065179
PMCPMC7736459

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.